GB201710879D0 - Methods and compounds for tumour-specific cell depletion - Google Patents

Methods and compounds for tumour-specific cell depletion

Info

Publication number
GB201710879D0
GB201710879D0 GBGB1710879.6A GB201710879A GB201710879D0 GB 201710879 D0 GB201710879 D0 GB 201710879D0 GB 201710879 A GB201710879 A GB 201710879A GB 201710879 D0 GB201710879 D0 GB 201710879D0
Authority
GB
United Kingdom
Prior art keywords
tumour
compounds
methods
specific cell
cell depletion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1710879.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Tusk Therapeutics Ltd
Original Assignee
Cancer Research Technology Ltd
Tusk Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, Tusk Therapeutics Ltd filed Critical Cancer Research Technology Ltd
Priority to GBGB1710879.6A priority Critical patent/GB201710879D0/en
Publication of GB201710879D0 publication Critical patent/GB201710879D0/en
Priority to US16/494,962 priority patent/US11879014B2/en
Priority to JP2019550705A priority patent/JP2020514363A/en
Priority to CR20190477A priority patent/CR20190477A/en
Priority to PCT/EP2018/056312 priority patent/WO2018167104A1/en
Priority to PE2019001847A priority patent/PE20191812A1/en
Priority to MX2019010974A priority patent/MX2019010974A/en
Priority to SG11201908578Y priority patent/SG11201908578YA/en
Priority to FIEP18711313.9T priority patent/FI3596123T3/en
Priority to AU2018233976A priority patent/AU2018233976A1/en
Priority to RS20240376A priority patent/RS65351B1/en
Priority to LTEPPCT/EP2018/056312T priority patent/LT3596123T/en
Priority to CN201880018976.8A priority patent/CN110869388A/en
Priority to BR112019017017A priority patent/BR112019017017A2/en
Priority to CA3056506A priority patent/CA3056506A1/en
Priority to KR1020197030283A priority patent/KR20190130137A/en
Priority to DK18711313.9T priority patent/DK3596123T3/en
Priority to EP18711313.9A priority patent/EP3596123B1/en
Priority to US16/628,713 priority patent/US20200283535A1/en
Priority to JP2019572678A priority patent/JP7225135B2/en
Priority to EP18742582.2A priority patent/EP3649153A1/en
Priority to PCT/GB2018/051923 priority patent/WO2019008386A1/en
Priority to CN201880045359.7A priority patent/CN111094346A/en
Priority to IL26908119A priority patent/IL269081A/en
Priority to CL2019002624A priority patent/CL2019002624A1/en
Priority to JP2024009215A priority patent/JP2024050684A/en
Ceased legal-status Critical Current

Links

GBGB1710879.6A 2017-03-17 2017-07-06 Methods and compounds for tumour-specific cell depletion Ceased GB201710879D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB1710879.6A GB201710879D0 (en) 2017-07-06 2017-07-06 Methods and compounds for tumour-specific cell depletion
US16/494,962 US11879014B2 (en) 2017-03-17 2018-03-03 Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
EP18711313.9A EP3596123B1 (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion
CN201880018976.8A CN110869388A (en) 2017-03-17 2018-03-13 Fc-optimized anti-CD 25 for tumor-specific cell depletion
KR1020197030283A KR20190130137A (en) 2017-03-17 2018-03-13 FC-optimized anti-CD25 for tumor specific cell depletion
PCT/EP2018/056312 WO2018167104A1 (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion
PE2019001847A PE20191812A1 (en) 2017-03-17 2018-03-13 COMPOUNDS AND METHODS FOR SPECIFIC CELL TUMOR REDUCTION
MX2019010974A MX2019010974A (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion.
SG11201908578Y SG11201908578YA (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion
FIEP18711313.9T FI3596123T3 (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion
AU2018233976A AU2018233976A1 (en) 2017-03-17 2018-03-13 Fc-optimized anti-CD25 for tumour specific cell depletion
RS20240376A RS65351B1 (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion
LTEPPCT/EP2018/056312T LT3596123T (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion
JP2019550705A JP2020514363A (en) 2017-03-17 2018-03-13 Fc-optimized anti-CD25 for tumor-specific cell depletion
BR112019017017A BR112019017017A2 (en) 2017-03-17 2018-03-13 method of treating a human individual who has cancer, anti-cd25 antibody, use of an anti-cd25 antibody, combination of an anti-cd25 antibody, kit for use in the treatment of cancer, pharmaceutical composition, combination, bispecific antibody, method of cancer treatment, and method of depleting regulatory t cells in an individual
CA3056506A CA3056506A1 (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion
CR20190477A CR20190477A (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion
DK18711313.9T DK3596123T3 (en) 2017-03-17 2018-03-13 FC-optimized anti-CD25 for tumor-specific cell depletion
CN201880045359.7A CN111094346A (en) 2017-07-06 2018-07-06 Compounds and methods for tumor-specific cell depletion
US16/628,713 US20200283535A1 (en) 2017-07-06 2018-07-06 Compounds and methods for tumour-specific cell depletion
JP2019572678A JP7225135B2 (en) 2017-07-06 2018-07-06 Compounds and methods for tumor-specific cell depletion
EP18742582.2A EP3649153A1 (en) 2017-07-06 2018-07-06 Compounds and methods for tumour-specific cell depletion
PCT/GB2018/051923 WO2019008386A1 (en) 2017-07-06 2018-07-06 Compounds and methods for tumour-specific cell depletion
IL26908119A IL269081A (en) 2017-03-17 2019-09-02 Fc-optimized anti-cd25 for tumour specific cell depletion
CL2019002624A CL2019002624A1 (en) 2017-03-17 2019-09-13 Compounds and methods for specific cell reduction.
JP2024009215A JP2024050684A (en) 2017-03-17 2024-01-25 Fc-optimized anti-CD25 for tumor-specific cell depletion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1710879.6A GB201710879D0 (en) 2017-07-06 2017-07-06 Methods and compounds for tumour-specific cell depletion

Publications (1)

Publication Number Publication Date
GB201710879D0 true GB201710879D0 (en) 2017-08-23

Family

ID=59676671

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1710879.6A Ceased GB201710879D0 (en) 2017-03-17 2017-07-06 Methods and compounds for tumour-specific cell depletion

Country Status (1)

Country Link
GB (1) GB201710879D0 (en)

Similar Documents

Publication Publication Date Title
IL269081A (en) Fc-optimized anti-cd25 for tumour specific cell depletion
IL263743A (en) Compositions and methods for the depletion of cells
IL268058B1 (en) Compositions and methods for the depletion of cd137plus cells
IL273915A (en) Cell
GB201813178D0 (en) Cell
GB201712733D0 (en) Methods & cells
GB201713078D0 (en) T Cell Modification
GB201707779D0 (en) Cell
GB201707783D0 (en) Cell
GB201803079D0 (en) Cell
IL292488B1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
GB201720949D0 (en) Cell
GB201718697D0 (en) Cell
GB201807693D0 (en) Cell
IL292482B2 (en) Azaindolylpyridone and diazaindolylpyridone compounds
GB201700404D0 (en) Compounds and composistions
GB201816399D0 (en) Cell
GB201805918D0 (en) Cell
GB201714718D0 (en) Cell
GB201714429D0 (en) Compounds and methods for tumour-specific cell depletion
GB201710879D0 (en) Methods and compounds for tumour-specific cell depletion
PT3596123T (en) Fc-optimized anti-cd25 for tumour specific cell depletion
GB201820443D0 (en) Cell
GB201810059D0 (en) Cell
GB201810070D0 (en) Cell

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)